Radiation Therapy

Phase 3Small molecule

Radiation Therapy is one of 70 small molecule programs targeting Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric Mucosa-Associated Lymphoid Tissue LymphomaActive, not recruiting

Multiple MyelomaActive, not recruiting

Merkel Cell CarcinomaRecruiting

Carcinoma, Non-Small-Cell LungActive, not recruiting

Stereotactic Body Radiation Therapy (SBRT)Recruiting

Gastric Mucosa-Associated Lymphoid Tissue LymphomaPhase 1

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Merkel Cell CarcinomaPhase 2

Recruiting

Carcinoma, Non-Small-Cell LungPhase 2

Active, not recruiting

Stereotactic Body Radiation Therapy (SBRT)Phase 3

Recruiting

Competition

Competitive Landscape

258 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 2

Biaxin

AbbVie

Phase 3

14 3

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

28 4

Mozobil

GGenzyme, a Sanofi Company

Phase 3

15 5

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

11 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 7

Etentamig

AbbVie

Phase 3

8 8

Daratumumab SC

Johnson & Johnson

Phase 3

5 9

Velcade

AZD0120

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Multiple Myeloma

NCT05336383

Q2 2027

Phase 3Recruiting

Stereotactic Body Radiation Therapy (SBRT)

NCT06065449

Q4 2027

Phase 2Active, not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02905591

Q2 2028

Phase 1Active, not recruiting

Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

NCT03680586

Clinical

Trials by Indication[1]

Lymphoma1 trial

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01132807·164 enrolled

Prostate Cancer1 trial

Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

Withdrawn·NNorthwestern University·Phase 2·NCT01087580

Stereotactic Body Radiation Therapy (SBRT)1 trial

A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases

Recruiting·MM.D. Anderson Cancer Center·Phase 3·NCT06065449·220 enrolled

Multiple Myeloma1 trial

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05336383·30 enrolled

Gastric Mucosa-Associated Lymphoid Tissue Lymphoma1 trial

Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Gastric MALT Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03680586·25 enrolled

3 more indications

Thoracic Cancer1 trial

MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07843537·30 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

A Phase 2 Trial of Pharmacological Ascorbate With Concurrent Chemotherapy and Radiation Therapy for Non-small Cell Lung Cancer

Active, not recruiting·JJoseph J. Cullen, MD, FACS·Phase 2·NCT02905591·43 enrolled

Merkel Cell Carcinoma1 trial

Hypofractionated Radiation Therapy for Merkel Cell Carcinoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05100095·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Radiation Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Radiation Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Radiation Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MM.D. Anderson Cancer Center

Radiation Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Lymphoma1 trial

Prostate Cancer1 trial

Stereotactic Body Radiation Therapy (SBRT)1 trial

Multiple Myeloma1 trial

Gastric Mucosa-Associated Lymphoid Tissue Lymphoma1 trial

Thoracic Cancer1 trial

Carcinoma, Non-Small-Cell Lung1 trial

Merkel Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News